Search results
Results From The WOW.Com Content Network
On July 8, 2010, Alcon's independent director committee (IDC) had set up a $50 million litigation trust to ensure company's minority shareholders get the best deal from bidder Novartis AG. [15] On April 9, 2019, Alcon completed a 100% spin-off from Novartis. [4] [16] [17] The new standalone company is worth up to 28 billion Swiss francs. [18]
The debut made Sandoz the largest new entrant to the Swiss stock exchange since 2019, when another Novartis spin-off, eyecare company Alcon, was valued at about 28 billion francs.
Julius Bär replaced by Alcon after a spin-off (5:1) from Novartis. [23] September 2020: Adecco replaced by Partners Group after the ordinary index review. [24] May 2021: LafargeHolcim renamed to Holcim. September 2021: Swatch Group was replaced with Logitech. [25] September 2022: SGS SA was replaced with Sonova. [26] June 2023
Novartis announces that it will spin-off its ophthalmology division, Alcon, into a separately-traded standalone company in order to focus on its legacy pharmaceuticals business.
Novartis' eye care unit Alcon is withdrawing a surgical stent for glaucoma patients after clinical data showed it may damage the eye, but the Swiss drugmaker said the move would not affect plans ...
Sandoz Group AG is a Swiss company that focuses on generic pharmaceuticals and biosimilars. [4] Prior to October 2023, it was part of a division of Novartis that was established in 2003, when Novartis united all of its generics businesses under the name Sandoz. Before this, the company existed as an independent pharmaceutical manufacturer until ...
Alcon is the world's largest and most profitable eye care company, Novartis said in a statement, with 2009 annual sales of $6.5 billion and net income of $2 billion. ... Novartis acquired a 25% ...
As part of his strategy, Narasimhan has divested the joint consumer healthcare venture to GSK, [24] the spin-off of Alcon, [25] and the exit of a stake in Roche [26] [20] as well as pushed for the acquisition of Advanced Accelerator Applications, Endocyte, AveXis, and The Medicines Company. [27] [28] [29]